Mark Agulnik, MD

Mark Agulnik, MD, discusses the efficacy and adverse events in the DeFi trial for patients with desmoid tumors given nirogacestat.

Mark Agulnik, MD, discusses the intricacies of desmoid tumors that can be recognized before starting treatment for patients.

Mark Agulnik, MD, discusses advances in determining the molecular drivers of the tumor in the sarcoma space.